Capmatinib (INC280) is a potent, selective, and orally active c-Met inhibitor (IC50 = 0.13 nM) that blocks c-Met signaling, suppresses tumor proliferation and migration, and induces apoptosis. It is metabolized primarily by CYP3A4 and aldehyde oxidase. Reagent grade, for research purpose.
Usually ships within 24 hours.